Literature DB >> 24241267

Factors associated with time-to-treatment of prostate cancer in Florida.

Hong Xiao, Fei Tan, Pierre Goovaerts, Georges Adunlin, Askal Ali, Youjie Huang, Clement K Gwede.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24241267      PMCID： PMC4337853          DOI： 10.1353/hpu.2014.0005

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN： 1049-2089


× No keyword cloud information.
  34 in total

1.  Differences in socioeconomic status and survival among white and black men with prostate cancer.

Authors:  A S Robbins; A S Whittemore; D H Thom
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

Review 2.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

3.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer.

Authors:  Willie Underwood; Sonya De Monner; Peter Ubel; Angela Fagerlin; Martin G Sanda; John T Wei
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

Review 4.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

5.  The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study.

Authors:  P N Post; B E Hansen; P J Kil; M L Janssen-Heijnen; J W Coebergh
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

6.  A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario.

Authors:  M Simunovic; A Gagliardi; D McCready; A Coates; M Levine; D DePetrillo
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

7.  Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.

Authors:  Robert K Nam; Michael A S Jewett; Murray D Krahn; Michael A Robinette; John Tsihlias; Ants Toi; Minnie Ho; Andrew Evans; Joan Sweet; John Trachtenberg
Journal:  Can J Urol       Date:  2003-06       Impact factor: 1.344

8.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

9.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

10.  How will the two-weeks-wait rule affect delays in management of urological cancers?

Authors:  K R Subramonian; S Puranik; G R Mufti
Journal:  J R Soc Med       Date:  2003-08       Impact factor: 18.000
View more
  3 in total

1.  Impact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.

Authors:  Pierre Goovaerts; Hong Xiao; Clement K Gwede; Fei Tan; Youjie Huang; Georges Adunlin; Askal Ali
Journal:  Spat Stat       Date:  2015-11-01

2.  Sociodemographic and Geographic Disparities of Prostate Cancer Treatment Delay in Tennessee: A Population-Based Study.

Authors:  Francisco A Montiel Ishino; Emmanuel A Odame; Kevin Villalobos; Claire Rowan; Martin Whiteside; Hadii Mamudu; Faustine Williams
Journal:  Am J Mens Health       Date:  2021 Nov-Dec

3.  Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital.

Authors:  Carolyn K Kan; Muhammad M Qureshi; Apar Gupta; Ankit Agarwal; Gretchen A Gignac; B Nicolas Bloch; Nicholas Thoreson; Ariel E Hirsch
Journal:  Adv Radiat Oncol       Date:  2017-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.